A Study of XmAb®662 as Monotherapy or in Combination With Pembrolizumab in Advanced Solid Tumors

Summary

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of intravenous administration of XmAb662 monotherapy or in combination with pembrolizumab in subjects with advanced solid tumors and to identify the recommended dose regimen that is safe and biologically effective for XmAb662.

Timeline

Start

2023-07-28

Primary completion

2024-05-21

Completion

2024-05-21

Outcome

Outcome not reported

Stopped (Business): “The Sponsor made a business decision to end the study.”

Drugs

Indications